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Introduction  
INTRODUCTION 
Diabetes mellitus is the commonest endocrine disease affecting 
mankind. The incidence of this disease continues to be on the rise all over 
the world. The magnitude of problem is further compounded by various 
catastrophic macro and microvascular complications targeting the vital 
organs in the body. 
Coronary artery disease (CAD) is the leading cause of death in 
patients with type 2 diabetes and is often asymptomatic because of silent 
myocardial ischaemia. The high mortality rate is partly due to the diabetic 
state per se, above and beyond the clustering of other risk factors such as 
hypertension, dyslipidemia, and obesity. The prevalence of CAD in our 
country earlier varied from 15 – 65/1000 population, but now it has 
increased to about 80 – 120/1000, making it a major cause of morbidity 
and mortality.
1
 
Coronary artery disease is multifactorial in etiology and has several 
important risk factors, out of which diabetes is one of the important 
modifiable risk factor. Data from Framingham heart study demonstrate 
the increased and poor prognosis of cardiac disease in diabetes. Mortality 
related to cardiovascular disease is doubled in diabetic men and 
quadrupled in diabetic women over that in their non diabetic 
counterparts.
2
 Diabetes is considered a ‘coronary artery disease (CAD) 
equivalent’ because patients with diabetes without known CAD have a 
similar cardiac event rate to patients without diabetes who had a prior 
myocardial infarction (MI).
2
 
CAD is the leading cause of morbidity and mortality in diabetic 
patients and frequently manifests itself silently and prematurely. Thus a 
classical cardiovascular risk factor is ‘HYPERGLYCEMIA’. Clinical 
evidence demonstrates that the hyperglycemia in diabetes correlates well 
with risk and severity of microvascular and macrovascular complications 
and improving hyperglycemia reduces this risk. CAD can be 
asymptomatic in diabetes and may present with sudden death, myocardial 
infarction, arrhythmia, silent myocardial ischemia or heart failure. The 
association between diabetes and asymptomatic CAD has been attributed 
to an autonomic neuropathy.
3
 Early detection of asymptomatic CAD in 
type 2 diabetes may prevent catastrophic cardiac events. However, 
periodical thorough clinical examination and resting E.C.G. may fail to 
detect coronary artery disease. Hence sophisticated cardio vascular non 
invasive tests should then be proposed for early detection of CAD in 
these patients. Exercise electrocardiograph can identify the majority of 
patients likely to have significant ischaemia during their daily activities 
and remains the most important screening test for significant CAD.
3
 This 
study was designed to evaluate asymptomatic coronary artery disease in 
selected diabetic patients by exercise treadmill test. 
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Aims & Objectives          
AIM AND OBJECTIVES 
1.  To study the prevalence of asymptomatic coronary artery disease in 
type 2 diabetes mellitus patients. 
2.  To study the relation of asymptomatic coronary artery disease with 
duration of diabetes mellitus 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Review of Literature            
REVIEW OF LITERATURE 
Diabetes mellitus is a heterogeneous group of metabolic disorders 
characterized by chronic hyperglycemia. Several distinct types of 
diabetes mellitus exist and are caused by a complex interaction of genetic, 
environmental factors, and life style choices. Depending on the etiology 
of diabetes mellitus, factors contributing to hyperglycemia may include 
reduced insulin secretion, decreased glucose utilization, and increased 
glucose production. The metabolic dysregulation associated with diabetes 
mellitus causes secondary pathophysiologic changes in multiple organ 
systems. Some forms of diabetes mellitus are characterized in terms of 
their specific etiology or pathogenesis, but the underlying etiology of the 
most common forms remains unclear. Persons developing the disease can 
be categorized according to clinical stages and other characteristics even 
in the absence of knowledge of the etiology. 
HISTORICAL ASPECTS  
“Diabetes is…a melting down of the flesh and limbs into 
urine…the flow is incessant, as if from the opening of aqueducts…The 
melting is rapid, the death speedy. Moreover, life is disgusting and 
painful.” – Arataeus Turkish physician from the second century AD. 
The knowledge of Diabetes mellitus dates back to centuries before 
Christ. The Egyptian Papyrus Ebers in 1500 BC described an illness 
associated with passage of “much urine”. Greek physician Arateaus of 
Coppadocia (200 AD) gave the word ‘diabetes’ meaning ‘running 
through a siphon’. Indians knew about the disease before Arateaus. An 
interesting amount of information is available from Charaka Samhita & 
Sushrutha Samhita compiled about 300 BC and 400 BC respectively. It 
was John Rollo (1809) who was one of the first to use adjunctive 
“mellitus” (mellitus: honey) to distinguish from other polyuric states in 
which urine was tasteless (Greek: insipidus). The 16th to 18th centuries 
have been termed the ‘DIAGNOSTIC’ period, as diabetes mellitus was 
then identified as a separate disease entity, while the mid to late 19th 
century may be regarded as the first ‘EXPERIMENTAL’ period, during 
which the glucoregulatory role of the pancreas became clear and the 
biochemical disturbances of diabetes were initially characterized.
5
 
Finally, the 20th century has seen a dramatic increase in knowledge about 
diabetes. The discovery of insulin in 1921-22 has had profound scientific, 
clinical and social consequences.
6
  
 
 
CLASSIFICATION OF DIABETES AND OTHER CATEGORIES 
OF GLUCOSE REGULATION   
Diabetes mellitus is classified on the basis of the pathogenic 
process that leads to hyperglycemia, as opposed to earlier criteria such as 
age of onset or type of therapy.
8
 
Etiologic classification of diabetes mellitus 
I.  Type 1 Diabetes (β-cell destruction, usually leading to absolute 
insulin deficiency) 
A) Immune-mediated                 B) Idiopathic 
II.  Type 2 diabetes (may range from predominantly insulin resistance 
with relative insulin deficiency to a predominantly insulin secretory 
defect with insulin resistance) 
III.  Other specific types of diabetes 
A. Genetic defects of β-cell function characterized by mutations in : 
1.  Hepatocyte nuclear transcription factor (HNF) 4α (MODY 1) 
2.  Glucokinase (MODY 2) 
3.  HNF – 1α (MODY 3) 
4.  Insulin promoter factor (IPF) 1 (MODY 4) 
5.  HNF – 1β (MODY 5) 
6.  Neuro D1 (MODY 6) 
7.  Mitochondrial DNA 
8.  Proinsulin or insulin conversion 
B. Genetic defects in insulin action 
1.  Type A insulin resistance 
2.  Leprechaunism 
3.  Rabson-Mendenhall syndrome 
4.  Lipodystrophy syndromes. 
C. Diseases of the exocrine pancreas – pancreatitis, pancreatectomy, 
neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous 
pancreatopathy. 
D. Endocrinopathies – acromegaly, Cushing’s syndrome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma 
E. Drug or chemical induced – Vacor, pentamidine, nicotinic 
acid,glucocorticoids, thyroid hormone, diazoxide, beta-adrenergic 
agonists, thiazides, phenytoin, α– interferon, protease inhibitors, 
clozapine, betablockers. 
F. Infections – congenital rubella, cytomegalovirus, coxsackie. 
G. Uncommon forms of immune-mediated diabetes – “stiff-man” 
syndrome, anti-insulin receptor antibodies. 
H. Other genetic syndromes sometimes associated with diabetes –
Down’s syndrome, Klinefelter’s syndrome, Turner’s syndrome, 
Wolfram’s syndrome, Friedreich’s ataxia, Huntington’s chorea, 
Laurence-Moon-Biedl syndrome, myotonic dystrophy, porphyria, Prader-
Willi syndrome. 
IV. Gestational diabetes mellitus (GDM) 
EPIDEMIOLOGY AND BURDEN OF TYPE-2 DM 
Diabetes mellitus is an “Iceberg” disease. According to recent 
estimates the prevalence of Diabetes mellitus in adults is around 6.4% 
worldwide. It is projected that the disease prevalence will be 7.8% by the 
year 2030, with global diabetic population reaching 438 million. Of this, 
close to 77% of the global burden of disease is projected to occur in 
developing countries. Type 2 DM forms 95% of all diabetes, an estimated 
30 million persons in the South-East Asian region are affected at present 
and it is estimated that by the year 2025 there will be nearly 80 million 
diabetics in this region, the highest among all WHO regions. Among this 
the greatest increase will be in India i.e. from 19.4 million (1995) to 57.2 
million by 2025. The prevalence of diabetics in Indian adults was found 
to be 2.4% in rural and 4-11.6% in urban dwellers. 
 
DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS 
•  Symptoms of diabetes plus random blood glucose concentration 
≥11.1 mmol/L (200 mg/dL)
a 
or 
•  Fasting plasma glucose ≥ 7.0 mol/L (126 mg/dL)
b
 or 
•  Two-hour plasma glucose ≥ 11.1 mmol/L (200 mg/dL) during an oral 
glucose tolerance test 
c
 
 
a) Random is defined as without regard to time since the last meal. 
b) Fasting is defined as no caloric intake for atleast 8 h. 
c) The test should be performed using a glucose load containing the 
equivalent of 75 g anhydrous glucose dissolved in water. 
  (source: Adapted from ADA,2004) 
The use of the hemoglobin A1C (HbA1C) for the diagnosis of 
diabetes is not recommended at this time. 
SCREENING FOR DIABETES 
Diabetes is frequently not diagnosed until complications appear 
and approximately one third of all people with diabetes may be 
undiagnosed. However, there are no randomized trials demonstrating 
benefits of early diagnosis through screening of asymptomatic 
individuals. But wide spread use of FPG as a screening test for Type 2 
diabetes mellitus is justified in individuals at high risk. 
TYPE 2 DIABETES MELLITUS 
This form of Diabetes mellitus was previously referred to as non-
insulin dependent Diabetes mellitus or adult onset diabetes. It is a term 
used for individuals who have insulin resistance and usually have relative 
insulin deficiency. Atleast initially and often throughout their life time, 
these individuals do not need insulin treatment to survive. There are 
probably many different causes of this form of diabetes, and it is likely 
that the proportion of patients in this category will decrease in the future 
as identification of specific pathogenic processes and genetic defects 
permits better differentiation among them and a more definitive 
subclassification.Many patients with this form of Diabetes mellitus are 
obese and obesity itself causes some degree of insulin resistance. Patients 
who are not obese by traditional weight criteria may have increased 
percentage of body fat distributed predominantly in the abdominal region. 
Ketoacidosis seldom occurs in this type of diabetes, it usually arises in 
association with the stress of another illness such as infection. This form 
of Diabetes mellitus frequently goes undiagnosed for many years because 
the hyperglycemia develops gradually and at earlier stages is often not 
severe enough for the patient to notice any of the classic symptoms of 
diabetes. Nevertheless, such patients are at increased risk of developing 
macrovascular and microvascular complications. The risk of developing 
this form of Diabetes mellitus increases with age, obesity and lack of 
physical activity. It occurs more frequently in women with prior 
Gestational Diabetes Mellitus (GDM) and in individuals with 
hypertension or dyslipidemia and its frequency varies in different 
racial/ethnic subgroups. It is often associated with a strong genetic 
predisposition; more so than is the autoimmune form of type 1 diabetes. 
However, the genetics of this form of Diabetes mellitus are complex and 
not clearly defined. 
PATHOGENESIS OF TYPE 2 DIABETES MELLITUS 
Type 2 diabetes mellitus is characterized by excessive increase in 
plasma glucose levels which results from failure in inhibition of hepatic 
glucose production in combination with reduction in uptake by tissues 
especially muscles. These abnormalities result from combination of 
inadequate insulin secretion and insulin resistance by both liver and 
muscle failure to suppress plasma glucose.  
Complications of Diabetes
8
 
 1. Acute complications 
a) Metabolic: Diabetic ketoacidosis, hyper osmolar non-ketotic coma, 
lactic acidosis and hypoglycemia.  
 b) Non metabolic: myocardial infarction, cerebrovascular stroke, 
overwhelming sepsis and infection.  
 2. Chronic complications 
Microvascular Macrovascular 
Retinopathy 
Nephropathy 
Neuropathy 
Diabetic foot ulcer 
Coronary artery disease (CAD/CHD) 
Cerebrovascular disease (CVD) 
Atherosclerotic arterial obstruction 
Others 
• Infections: UTI,Tuberculosis, Candidiasis – oral / volvovaginal, 
Mucor mycosis, Necrotising fasciitis, Periodontitis 
• Duputrens contracture 
• Pseudogout 
Diabetic Neuropathy 
 Diabetic neuropahy occurs in approximately 50% of individuals 
with long standing type 1 or type 2 diabetes mellitus. As with other 
complications of diabetes mellitus, the development of neuropathy 
correlates with the duration of diabetes and glycemic control. 
Classification 
Symmetric Asymmetric 
Distal sensory polyneuropathy 
Autonomic neuropathy 
Chronic  proximal motor neuropathy 
Acute or subacute proximal 
motor neuropathy 
Cranial mononeuropathy 
Truncal neuropathy 
Entrapment neuropathies 
DIABETIC RETINOPATHY 
Diabetic retinopathy is the most frequent cause of blindness among 
adults aged 20-74 years. During the first two decades of disease, nearly 
all patients with type 1 diabetes mellitus and >60% with type 2 diabetes 
mellitus have retinopathy. 
In type 2 diabetes mellitus, 21% of patients have retinopathy at 
first diagnosis. 
Classification 
10
 
Non Proliferative Diabetic Retinopathy (NPDR) 
Proliferative Diabetic Retinopathy 
 Advanced PDR 
 
Diabetic Nephropathy 
Diabetes has become the most common single cause of endstage 
renal disease (ESRD) world wide. About 20-30% of patients with type 1 
or type 2 diabetes mellitus develop evidence of nephropathy, but in type 2 
diabetes a considerably smaller fraction of these progress to ESRD. 
However, because of much higher prevalence of type 2 diabetes mellitus, 
these patients constitute over half of patients with nephropathy needing 
dialysis.
4 
CATEGORY Spot collection 
(µg/mg 
creatinine) 
24 Hr 
collection 
(mg/24 hrs) 
Timed 
collection 
(µg/min) 
Normal <30 <30 <20 
Microalbuminuria 30 – 299 30-299 20-199 
Clinical albuminuria ≥300 ≥300 ≥200 
The diabetic nephropathy progresses from appearance of low but 
abnormal levels of (≥ 30mg to 299 mg/day or 20µg/min) albumin in urine 
(stage of microalbuminuria) to stage of macroalbuminuria / clinical 
albuminuria (≥300mg/dl or ≥200µg/min) to ESRD. Progress from 
microalbuminuria to macroalbuminuria usually takes 10-15 years. ESRD 
develops in 50% of type 1 diabetic individuals with clinical nephropathy 
within 10 years and in 75% by 20 years. But in type 2 DM, even after 20 
years of overt nephropathy only 20% progress to ESRD. 
Screening for Microalbuminuria 
A test for the presence of urinary microalbumin should be 
performed at diagnosis in patients with type 2 diabetes mellitus and after 
5 years of disease duration in those with type 1 diabetes mellitus, then 
repeated annually.  
DIABETES MELLITUS AND CORONARY ARTERY DISEASE 
With  better control of metabolic and infective complications, 
diabetes has predominantly become a disease of the cardiovascular 
system. Cardio-Diabetology is emerging as a subspeciality throughout the 
globe to tackle the menace of cardiac related mortality in diabetes, 
particularly Type 2 DM. Diabetes mellitus has a greater prevalence of 
coronary artery disease, cardiomyopathy and congestive cardiac 
failure
12,13.
Diabetes not only involves the epicardial coronary arteries but 
also the intramural coronary arteries. Silent ischemic events constitute a 
special feature of presentation.CAD in DM patients is not only frequent 
but also occurs at younger age and the involvement is more extensive. 
The Framingham study has shown that cardiovascular mortality is 
twice in diabetic men and four times in diabetic women as compared with 
nondiabetic counter parts. Prevalence of angina pectoris is 60% greater in 
diabetic men and 90% greater in diabetic women than in a nondiabetics. 
Incidence of left main coronary artery is higher (13%) in diabetic versus 
non diabetic (60%), sudden death occurs 50% more in diabetic men and 
30% more in diabetic women. Prevalence of silent myocardial infarction 
and silent myocardial ischaemia is more in diabetics. In diabetes mellitus, 
there is greater prevalence of painless sudden death particularly during 
sleep. Silent myocardial ischaemia is evidenced during treadmill and 
thallium stress tests. Incidence of painless ST depression is twice in 
diabetics (75%) versus non diabetics (35%) 
In a study,16 of 30 asymptomatic diabetics with peripheral 
neuropathy, as determined by nerve function studies and compared them 
with 30 asymptomatic diabetics without evidence of neuropathy. All 
patients underwent exercise ECG and they found that 23.33% of all had 
abnormal responses. However, the two groups did not differ in prevalence 
of silent myocardial ischemia. 
Another study,
17
 evaluated the prevalence and characteristics of 
silent myocardial ischemia in 50 asymptomatic, non insulin dependent 
diabetes mellitus patients with normal resting electrocardiogram on 48 
hours holter monitoring.They found that prevalence of silent myocardial 
ischemia during daily activities in asymptomatic diabetic patients was 
very high (58%). Further, silent myocardial ischemia was related to the 
presence of other risk factors for coronary artery disease and to diabetic 
complications like retionopathy, neuropathy and nephropathy. However, 
silent myocardial ischemia was not related to cardiac autonomic 
neuropathy. 
In another study
18
 of 136 asymptomatic diabetics and 80 
asymptomatic controls with exercise ECG, 24 hour holter, Thallium 
Scintigraphy and coronary angiography. 29% diabetics and 5% controls 
were positive in one or more noninvasive test., 12/34 diabetic who 
underwent angiography had significant stenosis and 7 had unimportant 
stenosis, whereas only one control had unimportant stenosis. 30 diabetics 
with known or suspected CAD with exercise ECG and autonomic 
function test, they found that 60% had painless ST segment changes of 
those with severe autonomic neuropathy, 92% had no pain, whereas those 
with mild autonomic dysfunction or normal autonomic functions had 
39% prevalence of silent myocardial ischemia  
One study
21
 evaluated the significance of ischemic ST depression 
without anginal chest pain during exercise testing among patients with 
diabetes mellitus, using the data on 45 such patients from the Coronary 
Artery Surgery study registry. These patients (group 1 silent ischemia) 
were compared with 37 diabetic patients with both ischemic ST 
depression and chest pain (group 2 symptomatic ischemia), with 31 
diabetic patients without ischemic ST depression or chest pain (group 3 
no ischemia) and with 429 patients without diabetes who had silent 
ischemia during exercise testing. All patients had documented coronary 
artery disease (CAD) (70% diameter narrowing). The 6-year survival 
among patients with silent ischemia was worse in diabetic than non-
diabetic patients.  
A similar study of 58 asymptomatic male diabetics without prior 
evidence of CAD were evaluated with 24 hr. holter monitoring, exercise 
ECG, Thallium scintigraphy, autonomic tests and pain threshold 
measurement. They found that 36% had autonomic dysfunction and 17% 
had myocardial ischemia, which was more common in those with 
autonomic dvsfunction than those with normal autonomic function (38% 
vs 5%,). There was no difference in the somatic pain threshold. 
In another instance 40 consecutive diabetics on exercise ECG, 
autonomic testing and coronary angiography were studied
24
. They found 
37.5% to have silent ischemia with those with autonomic dysfunction 
having a greater prevalence of silent myocardial ischemia than those 
without (76.9% vs 25%). 
One study
25
 from India, evaluated 47 asymptomatic diabetics who 
underwent exercise ECG and autonomic function testing. 63.8% had >1 
autonomic test abnormal and 46.8% had >2 autonomic tests abnormal. 
38.3% had abnormal responses on TMT and those with autonomic 
dysfunction had a greater prevalence of silent ischemia than those without 
(59% vs 20%). Further, to validate the results coronary angiography was 
carried out in 9 patients who were TMT positive and 4 patients who were 
TMT negative. 8/9(88%) of the former and 1/4 (25%) of the later 
demonstrated significant coronary stenosis. 
Another study
26
 from India evaluated 20 male diabetic patients 
(age range, 40-60 years) with normal autonomic function were to 
determine the prevalence of silent myocardial ischemia on exercise as 
well as ambulatory electrocardiography. The presence and extent of silent 
myocardial ischemia was also correlated with the severity of 
atherosclerotic coronary artery disease as determined by coronary 
angiography. A cohort of 20 matched non-diabetic patients was also 
included in the study. Silent myocardial ischemia was detected in 50% of 
the diabetic patients on exercise electrocardiography and in 35% on 
ambulatory electrocardiography compared with 10% and 5% in non-
diabetics by the two methods, respectively. On exercise testing in diabetic 
patients, silent myocardial ischemia was detected in 64% of the patients 
with three-vessel disease; 50% of the patients with two-vessel disease and 
20% of the patients with one-vessel disease whereas in non-diabetic 
patients silent myocardial ischemia was detected in only 18% of the 
patients with three-vessel disease and in none of the patients with two-or 
one-vessel disease. On ambulatory electrocardiography, only patients 
with three-vessel disease manifested silent myocardial ischemia. Thus, 
silent myocardial ischemia occurs in diabetic patients with coronary 
artery disease more frequently even in the absence of autonomic 
dysfunction and the prevalence of silent myocardial ischemia is higher in 
patients with severe degree of coronary artery disease. 
One group
27 
evaluated the prevalence of silent myocardial ischemia 
in 925 non insulin dependent diabetes mellitus patients, aged 40 to 65 
years, asymptomatic, free from known coronary artery disease, advanced 
diabetic retinopathy and nephropathy with exercise electrocardiogram 
and thallium scintigraphy. The exercise tests were abnormal in 112 
patients (12.1%), of whom 59 (6.4%) had perfusion defects at thallium 
scintigraphy. Multivariate analysis showed that the associated 
independent risk factors were age, total cholesterol, proteinuria and ST-T 
abnormalities on electrocardiogram. 
Another group
28
 from India studied 30 asymptomatic myocardial 
ischemia in unselected middle aged diabetics and controls by holter 
monitoring, tread mill test and coronary angiography. ST segment 
depression was seen in 14 (46.7%) out of 30 diabetics and in 3 (10%) out 
of 30 controls on both holter and tread mill test (p=0.002). Coronary 
angiography done in patients with silent myocardial ischemia revealed 
higher prevalence of multi vessel involvement and diffuse disease in 
diabetics as compared to controls. 
In one more study
29
 from India, 120 asymptomatic stable type 2 
diabetics were assessed for the presence of silent myocardial ischemia by 
using TMT. They found that 51(42.5%) had evidence of myocardial 
ischemia on TMT, of these 18 underwent coronary angiography and 
significant CAD was found in 15(83.7%). 
In the Detection of Ischemia in Asymptomatic Diabetics (DIAD)
30
 
study,301123 patients with type 2 diabetes, aged 50-75 years, with no 
known or suspected CAD were randomly assigned to stress testing .The 
prevalence of ischemia in 522 patients randomized to stress testing were 
assessed myocardial perfusion imaging. A total of 113 / 522 patients 
(22%) had silent ischemia. The strongest predictors for abnormal tests 
were abnormal vasalva (odds ratio =5.6), male sex (2.5) and longer 
duration of diabetes (5.2). 
In a study
31
 including 500 patients with type 2 diabetes with no 
evidence of CAD on resting ECG found that 62(12.4%) patents exhibited 
abnormal changes on tread mill exercise test. CAD was diagnosed in 53 
individuals by coronary angiography. The abnormalities of exercise test 
were associated with the age of patients or the duration of diabetes 
(p<0.05). 
ETIOPATHOGENESIS OF CAD IN  DIABETES 
The pathogenesis of CAD in diabetes is multifactorial; 
hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, 
hypercoagulability and inflammation contributes to the etiology of CAD 
in diabetes. The most important structure in a blood vessel which bears 
the brunt of various pathogenic processes is the endothelial cell. 
Endothelial dysfunction is an early event in atherogenesis and may be 
seen long before any morphological changes demonstrated in the arterial 
wall. Endothelial injury may be a common pathway for various risk 
factors such as smoking, dyslipidemia and hypertension which produce 
endothelial cell dysfunction and produce vascular disease. Endothelium 
provides a non- permeable barrier to smooth flow of blood and its cellular 
components which do not adhere to the intact healthy endothelium. 
Various immune inflammatory process leading to endothelial injury 
produce a cascade of events which are summarised below 
32,33
 
Cascade of events leading to endothelial injury: 
1.  Endothelial injury with resultant increased permeability. 
2.  Migration of various cells into the subendothelial tissue. 
3.  Adherence of platelets to the subendothelial collagen. 
4.  Migration of macrophages into subendothelium and formation of 
foam cells forming fatty streaks. 
5.  Smooth muscle cell proliferation and plaque formation. 
6.  Platelet aggregation leading to thrombogenesis. 
7.  Vascular occlusion. 
SILENT MYOCARDIAL ISCHEMIA 
Ischemic chest pain is blunted in DM. The myocardial ischemia or 
infarction may be associated with mild symptoms or may be totally silent. 
In the Framingham study group 25% of the myocardial infarctions were 
unrecognized. Silent infarctions are more common in diabetes (39%) 
when compared to non diabetics (22%). Healed scars on the myocardium 
in the absence of ante-mortem history of infarction are 3 times more 
common on autopsy studies in diabetics than in non-diabetics. Similarly 
during treadmill exercise test, angina is absent during ischemic episodes 
(painless ST depression) almost twice in diabetics than in non-diabetics 
75% Vs 35%) and is due to severe autonomic neuropathy. Patients with 
diabetes who do experience angina became aware of their symptoms later 
in the course of ishcemia than do patients without diabetes. The delay in 
time from the onset of ST depression to angina may be twice as long to 
patients with diabetes than in patients without diabetes and correlates 
with the extent of autonomic nervous dysfunction. The incidence of 
severe disease of the left main coronary artery is also significantly higher 
in diabetic than nondiabetic patients (13% Vs 6%).
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Mechanism of Anginal Pain 
Anginal pain is frequently insufficiently sensitive. Pain stimuli 
arise with in the myocardium and most likely stimulate free nerve 
endings in the vicinity of small coronary vessels. Impulses travel in 
afferent unmyelinated (or) small myelinated cardiac sympathetic nerves 
though the upper 5 thoracic sympathetic ganglia to dorsal horn cells and 
through the spinothalamic tract to the thalamus and then to the cortex. At 
the cortical level, psychosocial and cultural factors may modulate the 
perception of pain.
40 
 
Diabetic patients have an increased incidence of painless Ml that is 
likely due, in part, to cardiac autonomic neuropathy. They have an 
increased prevalence, relative to non-diabetic patients of silent ischemia 
on exercise testing and ambulatory ECG monitoring. 
Cardiovascular autonomic neuropathy 
The development of symptomatic autonomic neuropathy in 
diabetics is an ominous sign with mortality over 50 per cent, three years 
after its onset. Generally parasympathetic fibers are affected first, leading 
to a relative increase in sympathetic tone that results in tachycardia and 
attenuation of the expected increase in heart rate and blood pressure with 
exercise. An absence of parasympathetic tone may worsen ischemia. 
Sympathetic nervous system dysfunction is usually evident within five 
years of the diagnosis of parasympathetic dysfunction. Postural 
hypotension is the classical clinical manifestation of sympathetic 
dysfunction. 
2,37,40,41,42,43 
Autonomic dysfunction in diabetes is multifactorial and may result 
from hyperglycemia-increased activity in the polyol pathway, altered 
myoinositol metabolism and non-enzymatic glycation. Other less 
understood mechanisms are alterations in nerve growth factor activity, 
blood viscosity, circulating platelets, transport of intraaxonal proteins and 
interaction between these pathways. The rationale for prevention of 
autonomic failure in DM is primarily to avoid sudden death in individuals 
with cardiovascular autonomic neuropathy during the metabolic demands 
imposed by anesthesia, surgery, physical, chemical or vascular stress, 
infection and exercise. 
Cardiac autonomic neuropathy in DM manifests as postural 
hypotension, painless Ml or even sudden cardiac death and is associated 
with high mortality. Cardiac autonomic neuropathy may be associated 
with dysautonomic neuropathy, gastroparesis, diabetic enteropathy, 
prolonged ileus, neuropathic bladder, impotence and sweating disorder. 
Autonomic neuropathy may be responsible for sudden death in persons 
with diabetes due to arrhythmia secondary to silent myocardial ischemia 
A relation exists between diabetic cardiac autonomic neuropathy and a 
prolonged QT interval on the ECG, which may predispose to life 
threatening ventricular arrhythmia. 
Autonomic neuropathy may lead to ischaemia or infarction by several 
routes:  
1.  By increasing myocardial demand for oxygen by increasing resting 
heart rate. 
2.  By reducing myocardial blood flow by increasing coronary vascular 
tone at the site of the coronary stenosis. 
3.  By reducing coronary perfusion pressure during orthostatic 
hypotension. 
CLINICAL TESTS OF AUTONOMIC FAILURE 
Cardiovascular Reflexes 
The tests described by Ewing are simple, not taking more than 20 
minutes and do not require elaborate equipment. Tests employing heart 
rate responses are mainly parasympathetic and tests measuring B.P. 
responses are mostly sympathetic. 
 
 
 
1. Heart rate responses (parasympathetic) 
a.  Heart rate response to valsalva maneuver. 
b.  Heart rate response during deep breath. 
c.  Heart rate response to standing. 
2. Blood pressure test 
a.  Blood pressure response to standing. 
b.  Blood pressure response to sustained handgrip. 
CAD in diabetes : Evaluation of myocardial ischemia
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CAD is a common cause of premature morbidity and mortality in 
diabetics. Evaluation of asymptomatic CAD in them is always a key 
issue. Early detection of CAD is therefore of paramount importance. 
Myocardial ischaemia may be asymptomatic or silent in a patient with 
known CAD, of the total ischaemic episodes only 20 to 30% are 
symptomatic and remaining 60 to 70% are silent, popularly known as 
silent myocardial ischemia (SMI). The occurrence of cardiac autonomic 
neuropathy dampens symptomatic episodes, making detection of SMI 
more crucial. 
ADA Consensus Guidelines for Cardiac Stress Testing in Diabetic 
Patients
5
 
Testing for CAD is warranted in patients with the following: 
• Typical or atypical cardiac symptoms 
• Resting electrocardiogram (ECG) suggestive of ischemia or 
infarction 
• Peripheral or carotid occlusive arterial disease 
• Sedentary lifestyle, age ≥35 years, and plans to begin vigorous 
exercise program 
Asymptomatic individuals 
Two or more of the risk factors listed below (a–e) in addition to diabetes: 
a)  Total cholestrol ≥240mg/dl,  LDL ≥160mg/dl, or  HDL ≤35mg/dl 
b)  Blood pressure >140/90mmHg 
c)  Smoking 
d)  Family history of premature CAD 
e)  Positive micro/macroalbuminura 
Evaluation of coronary artery disease 
1.  Resting ECG 
2.  Ambulatory ECG monitoring 
3.  Stress test: 
• Stress electrocardiography 
• Stress Echocardiography 
• Pharmacological stress echocardiography 
• Stress Thallium 
4. Coronary angiography 
5. Intracoronary vascular ultrasound 
The evaluation also includes other tests to evaluate associated risk 
factors like dyslipidemia, hypertension, glycosylation, coagulable state 
and platelet function. 
Resting ECG 
In diabetics, the resting ECG is normal in approximately one half 
of patients with chronic stable angina. In diabetics most common ECG 
abnormalities are non specific ST-T change with or without evidence of 
prior MI. 
There are numerous pitfalls in using resting ECG in diagnosis of 
myocardial ischemia in patients with diabetes. ST-T wave abnormalities 
are seen in common general population with an overall prevalence of 8.5 
percent for men and 7.7 %for women in the Framingham heart study. The 
prevalence increases with increasing age in the subjects with 
hypertension (HTN) and diabetes, in cigarette smokers and also in 
women. As the sensitivity and specificity of the resting ECG changes in 
patients with angina in diabetes is low, it cannot be relied to evaluate 
diabetes and angina with or without symptoms. A normal resting ECG 
does not exclude the presence of CAD. Severe triple vessel disease may 
exist with a normal resting ECG. A variety of conduction disturbances 
like left anterior fascicular block or LBBB may be seen in asymptomatic 
diabetics. These are often associated with poor ventricular function in 
diabetic heart disease with or without clinical myocardiàl ischemia. LVH 
on ECG may suggest associated hypertension in diabetes. 
Ambulatory 24 hrs electrocardiography 
It is used to detect Silent Myocardial Ischaemia (SMI) or 
ventricular arrhythmias in diabetic patients with suspected or established 
CAD and myocardial ischemia.. 
Ambulatory (Holter) electrocardiography technology 
The clinical utility of the ambulatory EGG recording lies in its 
ability to continuously examine a patient over an extended period of time, 
permitting patient ambulatory activity and facilitating the diurnal 
electrocardiographic examination of a patient in a changing 
environmental milieu (both physical and psychological). 
STRESS TESTING METHODS AND PROTOCOLS 
Numerous devices have been used to provide the dynamic exercise 
for exercise testing, including steps, escalators and ladder mills. Today, 
however, the bicycle ergometer and treadmill are the most commonly 
used dynamic exercise devices. 
 
MASTER’S TWO STEP TEST 
This test of Master was originally constructed as an exercise 
tolerance test rather than a screening test for coronary disease. The patient 
is made to walk to the top of the standardized two step staircase (each 9 
inches) and down the other side (18 inches). Then he turns round and 
climbs back the 18 inches step and gets down the two step staircase. This 
constitute one cycle. The patient now traverses the stairs proper number 
of times for his or her age and sex in 3 minute. A 12 lead ECG is taken 
before the test and lead V5 (or V4) should be sampled for 5-10 seconds 
every minute during exercise. The test is terminated when the patient 
completes the prescribed work load, or at the first appearance of chest 
pain, pallor or dyspnoea. The ECG is repeated. Master recommended that 
0.5 mm of ST depression be accepted as abnormal. The most important 
limitation of Master’s test is obviously that the amount of exercise given 
is usually insufficient and H.R. and BP are not measured during the test, 
thus no measurement is available to evaluate the percentage of maximum 
work. 
HARVARD STEP TEST 
This was developed in Harvard University Fatigue laboratory 
around 1940. It is basically an exercise tolerance test somewhat similar to 
the original master’s test before the ECG was applied. The patient is 
asked to step up and down on a 20 inch platform 20 times a minute for 5 
minutes. Pulse is counted during the recovery period and by calculation 
Harvard score is obtained. The limitations are same as in the Master’s 
test. 
BICYCLE ERGOMETER 
Bicycle ergometry has been widely used in Europe and South 
America. Dynamic exercise on a bike depends on the force applied as 
resistance to the pedals and the pedal rate. The bicycle may mechanically 
or electrically braked to increase the resistance. The advantages of the 
bicycle are that it is usually cheaper, takes up less space, and since upper 
body motion is reduced, it is easier to obtain BP measurements and obtain 
EGG. The patients body weight does not influence exercise capacity. In 
the opinion of Ellestad and many people in United States, treadmill 
applies a more physiologic workload and V02 max. values achieved were 
greater during treadmill exercise.  
TREADMILL 
The motor driven treadmill was introduced for clinical use in the 
1950’s. It is the most commonly used dynamic testing modality in the 
United States and India since most patients are more familiar with 
walking, than they are with bicycling. The use of treadmill presents a 
number of advantages because it is possible to adjust the speed and grade 
of walking to the agility of the subject. The workload can be increased by 
increasing the speed and / or grade. The starting speed of 1.7 mph at a 10 
percent grade recommended by Bruce and associates, resulting in an 
oxygen consumption of about 4 METs, has been very satisfactory. There 
are, however, reports of success with higher or lower speeds and inclines. 
The work load is better administered than with a bicycle ergometer since 
if the patient slows down he goes off the back of the treadmill. Despite 
these advantages, the treadmill presents several disadvantages. It is more 
expensive, occupies a considerably larger space, and is noisy, which 
makes it difficult to record BP and ECG at high speeds. 
ARM EXERCISE TESTING 
In subjects who are unable to exercise with their legs, because of 
orthopaedic problems or vascular insufficiency, arm ergometry provides 
an excellent substitute. 
ATRIAL PACING 
This test requires that a pacing catheter be placed in the right 
atrium. The correlation of heart rate and increased myocardial oxygen 
consumption indicates that at some heart rate, most patients with 
ischemic heart disease will have either chest pain or ischemic ST-
segments.  
 
DIPYRIDAMOLE TEST 
In patients who cannot walk on treadmill because of osteoarthritis, 
neurological deficits, etc, stress can be induced by Dipyridamole infusion 
at rate of 0.75 mg/kg/mm, over 4 min. ECG is to be recorded during post 
infusion period for about 6-10 minutes and to be compared with pre-
infusion ECG. 
TREADMILL PROTOCOLS 
The various protocols available for clinical use include an initial 
low load (warm up), and progressive increase in workload in stages. 
Though there are many protocols available for clinical use name will be 
ideal for every clinical situation. The suitability varies according to the 
objectives of the exercise test. For example, a vigorous exercise protocol 
may be suitable for screening a relatively healthy individual. On the other 
hand, a milder exercise protocol may be adequate for functional 
evaluation of a known cardiac patient and lighter workloads are needed 
for pre-discharge post infarction evaluation. Thus an ideal exercise 
protocol should have an initial workload well within a given individuals 
anticipated physical working capacity and the workloads, should be 
increased gradually and maintained for a sufficient length of time to 
achieve a near physiologic steady state. 
 
BRUCE PROTOCOL 
This is the most widely used protocol. It consists of 7 stages in 
which speed and grade are increased every 3 minutes. Bruce protocol has 
the advantage of being relatively short in duration. It also has many 
disadvantages. It’s high work loads may not be suitable for most cardiac 
patients or elderly sedentary individuals. The large increments in work 
make the estimation of maximal oxygen consumption less accurate. The 
fourth stage can either be run or worked, which results in differing 
oxygen costs.  
 
MODIFIED BRUCE PROTOCOL 
This protocol to an extent overcomes the disadvantages of the 
Bruce protocol. Here the first two stages are run at 1.7 mph at 0% and 5% 
grades. The third stage of modified Bruce corresponds to 1st stage of 
Bruce. The remaining stages corresponds to that of Bruce protocol. 
NAUGHTON’S PROTOCOL 
In this protocol the workloads are increased every two minutes. 
The increments being small and gradual, this protocol is quite useful in 
post myocardial infarction stress evaluation. 
Mc HENRY’S PROTOCOL 
It also provides a small initial workload and gradual increase every 
3 minutes. 
MODIFIED BALKE-WARE PROTOCOL 
This uses a constant brisk walking speed (3.4 mph) with 1% 
increase in grade every minute. 
ELLESTAD PROTOCOL 
In the Ellestad protocol, the speed is increased progressively every 
2 or 3 minutes during 7 stages with constant grade of 10% for the first 4 
stages and 15% for the last three stages.  
In summary, it is important to individualize the protocol election 
for the patient being tested. The optimal protocol is 6 to 10 minutes in 
length, endurance is tested rather than aerobic capacity. Exercise capacity 
should be reported in METS, not minutes. 
 
 
 
Fig 1 : Procedure of Treadmill 
 
 
 
Fig 2 : Treadmill 
  
 Fig 3 : Recordings of Stress ECG 
 
 
 
Fig 4 : Positive TMT Graph 
GENERAL INDICATIONS FOR EXERCISE TESTING
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CLASS-I 
1.  Diagnosis of CAD in patients with symptoms or other findings that 
are suggestive, but not diagnostic of coronary disease. 
2.  To assess functional capacity and to aid in assessing the prognosis 
of patients with known CAD. 
3.  To evaluate the prognosis and functional capacity of the patients 
with CAD after an uncomplicated myocardial infarction (before 
discharge or early after discharge). 
4.  To evaluate after coronary artery revascularization by CABG or 
coronary angioplasty. 
5.  Evaluation of arrhythmias. 
6. To evaluate functional capacity of selected patients with congenital 
heart disease. 
7.  To evaluate patients with rate-responsive pace makers. 
CLASS-II 
1.  Screening for latent CAD in asymptomatic patients over the age of 
40 with two or more risk factors for CAD. 
2.  Screening asympomatic patients over the age of 40 with special 
occupations (pilots, bus or truck drivers, rail road engineers etc). 
3.  To evaluate sedentary patients over the age of 40 who plan to enter a 
vigorous exercise program. 
4.  To evaluate patients with variant angina. 
5.  To evaluate functional capacity and response to drug therapy in 
patients with CAD or heart failure. 
6.  To evaluate patients who have sustained a complicated myocardial 
infarction but who have subsequently established (before or early 
after discharge). 
7.  Functional capacity of patients with valvular heart disease. 
8.  To follow up serially (at 1 year intervals or longer) patients with 
known CAD. 
9.  To evaluate on a routine, yearly basis patients who remain 
asymptomatic after a revascularization procedure. 
10.  To evaluate patients with resting ECG changes. 
CONTRAINDICATIONS
3,32,37 
The exercise ECG test is associated with a very low morbidity or 
mortality rate when the test is directly supervised by an experienced 
physician. A reasonable knowledge of the patient’s past medical history 
and present problems is essential. A fairly good idea of patient’s capacity 
to exercise can be obtained when this information is combined with 
auscultation of the heart and inspection of the resting ECG. Then, by 
carefully observing the patients response to early stages of the exercise 
protocol, the physician can be alerted to potential dangers and take steps 
to make certain that no harm is done. 
GENERAL CONTRAINDICATIONS TO EXERCISE TESTING  
Absolute contraindications 
1. Recent acute myocardial infarction (generally < 6 days). 
2.  Unstable progressive angina (including angina at rest). 
3.  Severe symptomatic left ventricular dysfunction. 
4.  Potentially life threatening cardiac dysarrhythmias like ventricular 
and atrial tachyarrhythmias and advanced second or third degree AV 
block. 
5.  Acute pericarditis, myocarditis and endocarditis. 
6.  Severe aortic stenosis. 
7.  Acute pulmonary embolus or infarction. 
8.  Acute or serious general illness like acute infections, hyperthyroidism 
or severe anemia. 
9.  Patients with locomotive problems (amputation severe arthritis or 
deformity) 
10.  Acute thrombophlebitis or deep vein thrombosis. 
11.  Known severe left main disease (> 70%). 
12.  Severe resting hypertension (> 240/130). 
RELATIVE CONTRAINDICATIONS 
1.  Any less serious non cardiac disorder (uncontrolled metabolic disease 
such as diabetes, myxoedema or thyrotoxicosis, asthma, hepatitis, 
pneumonic etc.) 
2.  Arterial hypertension (generally greater than 200 mmHg of systolic 
or 120 mmHg diastolic). 
3.  Moderate valvular or myocardial heart disease. 
4.  Known or suspected left main obstruction. 
5.  Hypertrophic cardiomyopathy with significant outflow obstruction.  
6.  Drug effect or electrolyte abnormalities (Digitalis intoxication, 
hypokalemia, tranquilisers, alcohol, disopyramide, quinidine, etc.) 
7.  Psychiatric disease. 
8.  Inability or lack of desire or motivation to perform the test. 
SAFETY PRECAUTIONS AND COMPLICATIONS 
SAFETY PRECAUTIONS 
As mentioned earlier, exercise testing should be performed only by 
well trained person with a basic working knowledge of exercise 
physiology. Although exercise testing is considered a safe procedure, 
there are reports of acute infarctions and deaths occurring secondary to 
this procedure. Keeping these things in mind certain safety precautions 
have to be taken. They may be summarized as follows: 
1.  Complete history and physical examination. 
2.  Indications and contraindications should be carefully considered. 
3.  Informed consent obtained before the exercise test for medicolegal 
purposes. 
4.  It is essential to take 2 sets of complete 12-lead electrocardiograms. 
Pre exercise ECG and post exercise ECG. 
5.  ECG (preferably 12 lead ECG) monitoring continuously during and 
after exercise until completion of the test (usually 8-10 minutes 
during recovery period). 
6.  Proper skin preparations and good quality electrodes are important to 
avoid artifacts and problems of interpretations. 
7.  BP should be recorded before, during and after test (ideally every 
minute). 
8.  The indications for termination of the test should be known 
thoroughly. 
9.  It is essential to have all necessary cardiopulmonary resuscitative 
facilities in the exercise laboratory, including a defibrillator and 
commonly used cardiac drugs.  
 
 
 
COMPLICATIONS 
Although exercise testing is considered a safe procedure in 
experienced hands, it is not without inherent risks, and the complications 
can and do occur.  
CARDIAC COMPLICATIONS 
1.  Hypotension and shock 
2.  Congestive heart failure 
3.  Severe cardiac dysarrhythmias 
4.  Myocardial infarction 
5.  Sudden death 
6.  Hypertension 
NON CARDIAC COMPLICATIONS 
1.  Musculo skeletal pain 
2.  Cerebrovascular accidents 
3.  Phlebitis  
CONDUCT OF EXERCISE TEST 
PATIENT PREPARATION 
Preparations for exercise testing include the following: 
1.  The patient should be instructed not to eat or smoke for 2 to 3 hours 
prior to the test and to come lightly dressed for exercise. 
2. A complete history and physical examination should be 
accomplished to rule out any contraindications for exercise testing. 
3
The use of certain medications like digitalis, beta blockers, calcium 
channel blockers, nitrates, which interface with the result of the 
exercise test should be curtailed wherever possible. In most of the 
exercise laboratories, drug therapy is withdrawn 24 to 48 hours 
before performing the test. 
4.  A resting 12 lead ECG should be obtained. This is important because 
detection of changes of acute MI may prohibit testing and detection 
of LBBB, LVH and WPW syndrome etc may make the interpretation 
more difficult. Another ECG should be recorded during 20-30 
seconds of hyperventilation as this procedure can produce ECG 
changes similar to ischemic patients. Appearance of such changes 
suggest the increased possibility of false positive test results. 
5.  Informed consent should be obtained after explaining the possible 
risks involved in exercise testing. 
6.  The testing procedure should be carefully explained to the patient 
and treadmill walking should be demonstrated. 
7.  Skin preparation and electrodes placement: The proper skin 
preparation is essential for obtaining high quality ECG recordings. 
The removal of superficial keratinised layer is the most important 
factor. The areas for electrode applications are first rubbed with an 
alcohol or acetone saturated guaze (after shaving hairy chest) to 
remove the superficial only layer. Then these area re rubbed with 
fine sand paper or rough material to obtain good electrode contact. 
This reduces the contact impedance from 10-50 k. ohms to 1-5 k 
ohms. The most reliable electrodes are light weight liquid contact 
silver chloride electrodes. Since a standard 12 leads ECG with 
electrodes placed on the limbs could not be obtained during exercise, 
other electrode placements have been used. The arm electrodes and 
lower limb electrodes are brought on to the trunk and placed at sites 
nearest to the respective limbs. This modified placement (Mason-
Likar modification) lessening the motion artifact without producing 
much difference from the standard 12 lead ECG. 
END POINTS 
TARGET HEART RATE APPROACH 
Many exercise laboratories employ submaximal tests, in which 
target heart rate and points correspond to 85 to 90% of the predicted 
maximal heart rate observed in normal subjects (220 - age in years). The 
test is terminated prematurely if there are an other indications for 
stopping the test. The submaximal testing is often predicted on the 
mistaken assumption that such a testing is safer than symptom limited 
testing. However, the poor relationship between maximal heart rate and 
age must be understood. The THR approach has major limitations in 
patients receiving beta adrenergic blocking agents and in those with heart 
rate impairment on exercise heart rate response. 
SYMPTOM LIMITED TESTING 
This is performed in almost all circumstances except very soon 
(i.e., 10-14 days) after acute cardiac events such as myocardial infarction 
and CABG surgery symptom limited testing has been safely performed as 
soon as 72 hours after the last episode of chest pain in patient’s admitted 
to hospital for unstable angina (MI ruled out). 
INDICATIONS FOR TERMINATION OF EXERCISE TEST
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In a patient with known or suspected heart disease, the physician 
administering the test must continuously observe the patient and the 
monitor. The electrocardiographic printout is often more informative than 
the image on the oscilloscope and must be available for immediate 
infarction whenever needed. 
The indications for termination of an exercise tests have been 
summarized below: 
1.  Anginal pain is progressive. 
2.  Drop in systemic blood pressure below the resting value or non 
raising SBP with continued exercise. A fall of more than 20 mmHg 
in systolic pressure occurring after the normal initial rise. 
3.  Frequent premature ventricular contractions developing in pairs or 
with increasing frequency as exercise increases or ventricular 
tachycardia and ventricular fibrillation development. 
4.  Atrial tachycardia, atrial fibrillation or atrial flutter supervenes. 
5.  Hypertensive response of SBP>280 mmHg and diastolic BP > 140 
mmHg. 
6. Onset of second or third degree heart block. 
7.  ST segment depression has become marked. Most would terminate 
the exercise at 3mm or more ST depression. 
8.  ST segment elevation of 2 mm or more. 
9.  Patient is unable to continue because of dyspnoea fatigue or feeling 
of faintness or dizziness. 
10.  Signs of poor perfusion like pallor, cyanosis and cold extremities and 
sweating. 
11.  Marked apprehension, mental confusion or lack of coordination. 
12.  Technical problems with monitoring the ECG or systolic blood 
pressure. 
13.  Patient’s request. 
14.  Development of bundle branch block that cannot be distinguished 
from ventricular tachycardia. 
15.  When the patient has reached or exceeded the predicted maximal 
heart rate, one can be satisfied that the patient has performed 
satisfactorily. However, if the subject is able and willing to continue, 
one can safely proceed if there are no other indications for 
termination. Patients should understand that they can stop 
voluntarily, but are encouraged to try to reach or exceed maximum 
predicted heart rate. When performed in patients with a high 
likelihood of coronary artery disease, the positive and negative 
predictive values of exercise testing are high, with a sensitivity and a 
specificity ranging from 60% to 90%.
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Materials & Methods  
MATERIALS AND METHODS 
The present study was conducted in the CMC Hospital, 
Coimbatore during the period of September  2009  to september 2010. 
Study Design 
One year cross sectional study on the patients of type 2 diabetes 
mellitus without any clinical and electrocardiographic evidence of 
coronary artery disease. 
Source of data 
The patients of type 2 diabetes mellitus without clinical evidence of 
coronary artery disease attending diabetic clinic and medicine OPD, 
CMC Hospital, Coimbatore were enrolled in the study. 
Sample Size 
Total of 50 patients included in the study. 
Inclusion Criteria 
1.  Patients of type 2 diabetes mellitus without clinical evidence of  CAD 
2.  Normal resting 12 lead ECG 
3.  No past history of ischaemic heart disease, CVA and hypertension. 
 
 
Exclusion Criteria 
1.  Patients having symptoms and signs suggestive of ischaemic heart 
disease. 
2.  Abnormal resting 12 lead ECG 
3.  Presence of risk factors known to predispose to ischaemic heart 
disease. 
a.  Hypertension. 
b.  Evidence of CAD  
c.  Vascular disease (Cerebrovascular accident, peripheral vascular 
disease). 
d.  Cigarette smoking. 
e.  Patients on oral contraceptive pills. 
Methods and collection of Data 
All the patients attending to diabetic clinic and medicine OPD, 
CMC Hospital, Coimbatore were screened for eligibility. The eligible 
patients were given an informed consent. The consented participants were 
enrolled in the study. Descriptive data of the participants like name, age, 
sex, personal history, occupational, were obtained by interviewing the 
patients. Each of the patient’s proper history were recorded on 
predesigned and pretested proforma. They underwent a thorough physical 
examination.  
HISTORY AND EXAMINATION 
A detailed history was elicited from all patients with emphasis on 
duration of diabetes mellitus, symptomatology of diabetes mellitus and its 
various microangiopathic complications. 
Body mass index (BMI) was calculated according to Quetelet’s 
formula and subjects accordingly categorized. 
Type BMI Kg/m
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Normal 18.5 – 24.9 
Overweight 25 – 29.9 
Obesity 30 – 39.9 
Morbid obesity >40 
A meticulous systemic examination was conducted in all patients 
including fundus examination to find diabetic retinopathy and  special 
emphasis was laid on autonomic neuropathy. 
Tests for autonomic neuropathy 
1) Resting heart rate > 100 beats/min is abnormal 
2) Beat-to-beat heart rate variation  
With the patient at rest and supine (no overnight coffee or 
hypoglycemic episodes),  breathing  6 breaths/min, heart rate monitored, 
a difference in heart rate of > 15 beats/min is normal and < 10 beats/min 
is abnormal. 
3) Systolic blood pressure response to standing 
          Systolic blood pressure is measured in the supine subject. The 
patient stands and the systolic blood pressure is measured after 2 min. 
Normal response is a fall of < 10 mmHg, borderline is a fall of 10-29 
mmHg, and abnormal is a fall of > 30 mmHg with symptoms.  
Autonomic dysfunction defined as 2 or more abnormal responses. 
INVESTIGATIONS 
All patients were subjected to the following investigation at the 
time of inclusion into the study. 
• Routine hemogram 
• Fasting and post prandial blood sugar 
• Glycosylated hemoglobin 
• Lipid profile(total cholesterol, triglycerides, LDL, HDL) 
• Blood urea and serum creatinine 
• Urine routine and microscopic examination 
• X-ray chest (PA view) 
• Resting Electrocardiogram 
• Tread mill testing 
Technique of treadmill test 
The patient is instructed not to eat or drink caffeinated beverages 
three hours prior to testing and to wear comfortable shoes and loose 
fitting clothes. A brief physical examination performed prior to the test 
and a written informed consent taken. A standard 12 lead ECG taken 
following which a torso ECG obtained in the supine position and in the 
sitting or standing position. Blood pressure recorded in both positions and 
the patient  instructed on how to perform the test. Standard multistage 
maximal exercise test done on a motorised treadmill according to Bruce 
protocol. The heart rate, blood pressure and electrocardiograms recorded 
at the end of each stage of exercise, immediately before and after 
stopping the exercise and for each minute for at least 5 to 10 minutes in 
the recovery phase. Exercise test terminated in all patients following the 
achievement of target heart rate or an abnormal ischemic response. This 
is defined as development of 0. 10 mV (1mm) of J point depression 
measured from the PQ junction, with a relatively flat ST segment slope 
(<lmV/sec), depressed ≥ 0.10 mV 60 to 80 msec after the J point in three 
consecutive beats with a stable baseline. Exercise test also terminated if 
patient develops dysponea, fatigue or chest pain 
 
 
 
 
  
 
 
 
Results and Analysis                  
RESULTS & ANALYSIS 
DATA ANALYSIS 
A total number of 50 cases of type 2 diabetes mellitus without 
clinical and ECG evidence of CAD were studied and the following 
observations were noted. 
Age 
The mean age of the study subjects was 50.56 years; standard 
deviation (SD) of 7.59 years. Most of the patients belonged to the age 
group 40 – 60 years. 
Sex 
Out of 50 cases, 40 were males and 10 were females. The ratio of 
males to females was 4:1. 
 
TABLE - 1 
AGE AND SEX CORRELATION 
Age in years Male Female Total 
30-39 04 02 06(12%) 
40-49 16 04 20(40%) 
50-59 15 03 18(36%) 
60-69 05 01 06(12%) 
Total 40 10 50 (100%) 
 
 
6 patients (12%) in the study were in the age group of 30 – 39 
years. Of these 4 were males and 2 were females . 20 patients (40%) were 
in the age group of 40 – 49 years. Of these 16 were males and 4 were 
females. 18 patients (36%) in the study were in the 30 – 59 age group, of 
these 15 were males and 3 were females. 6 patients (12%) were in the age 
group of 60 –69 years, of these 5 were males and 1 was female. Most 
patients were between the age group of 40-60 years. 
TABLE - 2 
PARAMETERS 
S 
No. 
Parameter 
Males  n=40 
Females  
n=10 
P 
value 
Inference 
Mean SD Mean SD 
1 Age in yrs 50.78 7.45 49.70 8.47 0.69 NS 
2 BMI(kg/m
2
) 25.30 4.08 23.4 5.50 0.24 NS 
3 Pulse per mt 79.05 7.81 77.5 5.19 0.55 NS 
4 SBP mm Hg 132.40 7.00 130 7.24 0.35 NS 
5 DBP mm Hg 83.35 6.46 84 6.99 0.78 NS 
6 HBA1C % 8.61 1.11 8.86 2.02 0.60 NS 
7 TCholesterol 191.05 34.23 187.3 32.21 0.7554 NS 
8 TGL 135.83 36.84 130.7 51.35 0.7184 NS 
9 LDL 127.88 29.22 126.00 23.75 0.8520 NS 
10 HDL 36.03 3.53 35.10 3.60 0.4636 NS 
11 FBS 162.87 45.67 163.90 25.53 0.94 NS 
12 PPBS 216.97 66.03 229.40 53.43 0.58 NS 
Statistically, no significant difference was seen between the sexes 
as far as their mean age, BMI, Pulse, Systolic blood pressure, Diasolic 
blood pressure, HbA1C, Total cholesterol, Triglycerides, LDL, HDL, 
FBS and PPBS was concerned 
TABLE - 3 
BODY MASS INDEX 
BMI No: of patients Percentage 
Normal(18.5 – 24.9) 29 58% 
Overweight (25 – 29.9) 16 32% 
Obese (30 – 39.9) 5 10% 
Total 50 100% 
29 (58%) patients were with normal body mass index, 16 patients (32%) 
were overweight while only 5 (10%) patients were obese. 
TABLE - 4 
DURATION OF DIABETES MELLITUS 
Duration of DM Male Female Total 
<5 25 (62.5%) 05 (50%) 30 (60%) 
6-10 08 (20%) 02 (20%) 10 (20%) 
11-15 06 (15%) 01 (10%) 07 (14%) 
16-20 01 (2.5%) 02 (20%) 03 (06%) 
Total 40 (100%) 10 (100%) 50 (100%) 
In the study population, more number of patients (30 i.e. 60%) 
were having diabetes equal to or less than 5 years, followed by 10 
patients (20%) with the duration of 6 to 10 years, next 7 patients (14%) 
between 11 to 15 years and only 3 patients(6%) between 16 to 20 years. 
 
TABLE - 5 
GLYCOSYLATED HEMOGLOBIN AND DURATION OF 
DIABETES MELLITUS 
Duration 
of DM 
Average Glycosylated Hemoglobin 
6-8 8-10 10-12 12-14 Average 
<5 7.50 8.70 10.5 14 8.50 
6-10 7.58 8.80 11.2 - 8.55 
11-15 8.0 9.85 11.45 - 9.36 
16-20 8.0 9.60 - - 9.07 
 The average glycosylated hemoglobin (HbA1C) was 8.50, 8.55, 
9.36 and 9.07 for the duration of diabetes equal to or less than 5 yrs ,6 to 
10 yrs, 11 to 15 yrs and 16 to 20 yrs respectively. This shows that all 
patients had poor glycaemic control. 
TABLE - 6 
MODE OF TREATMENT 
Duration of 
DM 
Diet OHA Insulin 
OHA & 
Insulin 
Total 
<5 01 18 09 02 30 
6-10 - 06 02 02 10 
11-15 - 03 01 03 07 
16-20 - - - 03 03 
Total 
01  
(02%) 
27 
(54%) 
12 
(24%) 
10  
(20%) 
50 
(100%) 
 In 50 patients, 1(2%) was on diet control alone, 27 (54%) were on 
one or the other OHA’s, 12 (24%) were on one or the other form of 
insulin while 10 (20%) were receiving both oral hypoglycaemic agents 
and insulin. 
TABLE - 7 
SYMPTOMATOLOGY 
Duration of 
DM 
Symptoms of 
DM 
Symptoms of 
Peripheral 
Neuropathy 
Symptoms of 
Autonomic 
Neuropathy 
<5 05 05 02 
6-10 02 02 01 
11-15 02 05 02 
16-20 02 03 01 
Total 11 15 06 
 This table depicts the symptoms of diabetes and microangiopathic 
complications of the study population at the time of inclusion into the 
study. Of the 50 patients only 11 (22%) had symptoms of diabetes, 15 
(30%) had symptoms of peripheral neuropathy while only 6 (12%) had 
symptoms of autonomic neuropathy. None of the patients had symptoms 
of nephropathy and retinopathy. 
TABLE - 8 
BLOOD LIPID PROFILE 
Duration 
of DM 
Av.Cholesterol Av. TGL Av. HDL Av. LDL 
Mean SD Mean SD Mean SD Mean SD 
<5 183.50 29.75 131.6 32.94 121.30 25.78 35.87 3.23 
6-10 190.80 28.64 123.3 32.03 130.40 23.78 35.8 3.49 
11-15 197.14 45.20 142.86 57.94 132.29 33.76 36.29 4.96 
16-20 240.67 16.01 186.33 54.59 168.67 18.93 34.67 4.62 
This table shows the blood lipid profile of the study subjects. 
Statistically there was no significant difference in average cholesterol, 
tryglicerides, LDL and HDL with respect to the duration of diabetes 
mellitus (p = > 0.05) 
TABLE - 9 
CLINICAL SIGNS OF NEUROPATHY 
Duration of 
DM 
No of patients 
Peripheral 
Neuropathy 
Autonomic 
Neuropathy 
<5 30 06 03 
6-10 10 02 03 
11-15 07 07 03 
16-20 03 03 03 
Total 50 18 12 
  
This table represents the incidence of diabetic neuropathy on 
systemic examination with regard to duration of diabetes mellitus. Out of 
50 patients,18(36%) had clinical signs of peripheral neuropathy and 
12(24%) had signs of autonomic neuropathy. Of diabetes of <5 years 
duration 6 patients revealed signs of peripheral neuropathy while 3 had 
evidence of autonomic neuropathy. 2 patients with diabetes of duration 
between 6 and 10 years had signs of peripheral neuropathy while 3 had 
autonomic neuropathy. All the 7 patients with diabetes of duration 
between 11 and 15 years had signs of peripheral neuropathy while 3 had 
signs of autonomic neuropathy. All the 3 patients with duration of 
diabetes between 16 and 20 years had signs of peripheral neuropathy as 
well as autonomic neuropathy. 
TABLE - 10 
TMT RESULTS 
TMT Result Male Female Total 
Positive 11 (27.5%) 04 (40%) 15 (35%) 
Negative 29 (72.5%) 06 (60%) 35 (65%) 
Total 40 (100%) 10 (100%) 50 (100%) 
Table X shows the prevalence of asymptomatic coronary disease in 
the study population.Among 50 patients, TMT was positive in 15 (30%) 
and TMT was negative in 35 (70%) patients. Out of 15 positive cases 11 
were males and 4 were females 
 TABLE - 11 
TMT RESULTS AND DURATION OF DIABETES MELLITUS 
Duration of 
DM 
TMT Positive TMT Negative Total 
<5 05 (16.67%) 25 (83.33%) 30 (100%) 
6-10 03 (30%) 07 (70%) 10 (100%) 
11-15 05 (71.44%) 02 (18.56%) 07 (100%) 
16-20 02 (66.67%) 01 (33.33%) 03 (100%) 
Total 15 (30%) 35 (70%) 50 (50%) 
This table shows the relation of asymptomatic coronary artery 
disease and duration of diabetes mellitus. In the present study out of 50 
patients, TMT was positive in 15 (30%) and negative in 35 (70%) 
patients. TMT was positive in 5/30 (16.67%), 3/10 (30%), 5/7 (71.44%) 
and 2/3 (66.67%) patients with duration of diabetes ≤ 5, 6 to 10, 11 to 15 
and 16 to 20 years respectively. This shows longer the duration of 
diabetes, greater the risk of asymptomatic coronary artery disease. 
TABLE - 12 
COMPARISON OF DIABETIC SUBJECTS WITH AND 
WITHOUT ASYMPTOMATIC CAD 
Characteristics 
TMT 
positive 
TMT 
negative P 
value 
Inference 
Mean SD Mean SD 
Average age 57.40 7.47 47.63 6.80 0.000 S 
Av. Duration of DM 9.58 5.08 4.69 4.11 0.0026 S 
Av. BMI 23.08 4.67 25.67 4.69 4.67 NS 
Av. HbA1C 9.19 0.89 8.43 1.128 0.0619 NS 
Av. FBS 16.160 45.30 163.71 46.18 0.87 NS 
Av.PPBS 201.12 61.0 227.23 63.53 0.18 NS 
Av. T. Cholesterol 201.33 32.26 185.57 32.06 0.1292 NS 
Av.TGL 156.60 38.56 125.46 32.05 0.0094 S 
Av. LDL 133.67 26.63 124.86 28.44 0.3127 NS 
Av. HDL 36.33 3.46 35.63 3.31 0.5226 NS 
 
The observations made with tread mill testing with reference to 
average age, duration of diabetes, triglyceride levels was found to have 
statistically significant difference in TMT positive cases and TMT 
negative cases. Average age in TMT positive and negative cases was 57.4 
and 47.63 yrs respectively. Average duration of diabetes in TMT positive 
and negative cases was 9.5 and 4.69 years respectively. Average 
triglyceride levels in TMT positive and negative cases was 156.60and 
125.46 mg% respectively. 
TABLE - 13 
DIABETIC PERIPHERAL NEUROPATHY AND 
ASYMPTOMATIC CAD 
Diabetic patients TMT result Total 
n=50 Positive(n=15) Negative(n=35) 
With peripheral 
neuropathy 10 8 18 
Without peripheral 
neuropathy 5 27 32 
10 (55.55%) of the 18 diabetics with peripheral neuropathy had 
asymptomatic coronary artery disease while 5 (15.62%) of the 32 
diabetics without peripheral neuropathy had asymptomatic coronary 
artery disease. This shows diabetics with peripheral neuropathy had 
higher incidence of asymptomatic coronary artery disease than those 
without it. (55.5% Vs 15.62%). 
 
TABLE - 14 
DIABETIC AUTONOMIC NEUROPATHY AND 
ASYMPTOMATIC CAD 
Diabetic patients TMT result Total 
n=50 Positive(n=15) Negative(n=35) 
With autonomic 
neuropathy 09 03 12 
Without autonomic 
neuropathy 06 32 38 
 
 
09 (75%) out of 12 diabetics with autonomic neuropathy had 
asymptomatic coronary artery disease while 06 (21.95%) out of 38 
diabetics without autonomic neuropathy had asymptomatic coronary 
artery disease. This shows diabetics with autonomic neuropathy had 
higher incidence of asymptomatic coronary artery disease than without it 
(75% Vs 21.95%). 
  
 
 
 
Discussion   
DISCUSSION 
Coronary and peripheral vascular atherosclerosis is one of the most 
common and chronic complication of diabetes mellitus. A recently 
observed and focused aspect of coronary artery disease is its silent and 
asymptomatic presentation. The present study was aimed at the 
asymptomatic presentation of coronary artery disease in diabetes mellitus 
patients. It consist of two aspects; first the prevalence of asymptomatic 
coronary artery disease in diabetes mellitus, secondly, relation between 
duration of diabetes mellitus and asymptomatic coronary artery disease. 
This study consisted of 50 known diabetics without clinical and 
ECG evidence of CAD and were evaluated for the prevalence of 
asymptomatic CAD by using exercise Tread mill testing. In the present 
study, 40 were males and 10 were females with mean age of 50.56 years 
;SD  of 7.59 years. Of the total, 16 patients (32%) were overweight , 5 
patients (10%) were obese and remaining were with normal BMI. In our 
study population, more number of patients (30 i.e 60%) were having 
diabetes of duration equal to or less than 5 years, followed by 10 patients 
(20%) with the duration of 6 to 10 years, 7 patients(14%) with duration of 
11 to 15 years and only 3 patients(6%) with 16 to 20 years of duration. In 
our 50 patients, 1(2%) was on diet control alone, 27 (54%) were on one 
or the other OHA’s, 12 (24%) were on one or the other form of insulin 
while 10 (20%) were on both oral hypoglycaemic agents and insulin. 
Also it was observed that patients with shorter duration of diabetes were 
on OHA’s and patients with longer duration of diabetes were on either 
insulin alone or on both insulin and OHA’s. Among 50 patients, TMT 
was positive in 15 (30%) and was negative in 35 patients (70%). Out of 
15 positive, 11 were males and 4 were females. The prevalence of 
asymptomatic CAD in type 2 diabetes mellitus was found to be 30%( 
15/50). 
Our findings were similar to previous studies. One study
18
 found 
that 29% diabetics who were asymptomatic for coronary artery disease 
had silent myocardial ischaemia on 24 hour ambulatory monitoring 
exercise electrocardiogram. Another group
23
 found 31% diabetics without 
prior evidence of CAD had treadmill test positive and silent myocardial 
ischaemia was 2.2 times more common in diabetics as compared with non 
diabetics. 
A study
25
 in India found that 38.3% of diabetics without prior 
coronary artery disease had silent myocardial ischaemia on exercise test. 
Another study
26 
from India, reported 50% incidence of silent myocardial 
ischaemia in diabetics on exercise electrocardiogram and 35% on 
ambulatory monitoring. One of the study
44
 concluded that the prevalence 
of silent myocardial ischaemia by using exercise ECG was 17% and 
angiographic coronary artery disease was found in 13% of middle aged 
subjects with type 2 diabetes mellitus without other cardiovascular risk 
factors. 
The other study
29
 from India, found that 42.5% had evidence of 
silent ischemia on tread mill testing. Of these 83.7% was found to have 
significant CAD in  coronary angiography . 
So, the present study is in agreement with that diabetics have a higher 
prevalence of asymptomatic coronary artery disease. 
Duration of type 2 diabetes mellitus and coronary artery disease 
In 50 of our patients, TMT was positive in 15 patients (30%) and 
was negative in 35 patients (70%) .30 patients with diabetes of duration 
equal to or less than 5 years, TMT was positive in 5 (16.67%).10 patients 
with diabetes of duration between 6 to 10 years, TMT was positive in 3 
(30%).7 patients with duration of diabetes between 11 and 15 years, TMT 
was positive in 5 (71.44%).3 patients with diabetes of duration between 
16 and 20 years, TMT was found to be positive in 2 (66.67%). 
Our results are similar to one study
45
 who found that 70% subjects 
with diabetes of more than 5 years duration had associated silent 
myocardial ischemia while only 30% subjects with diabetes of less than 5 
years duration had associated silent myocardial ischemia. Another study
31 
including 500 patients with type 2 diabetes mellitus with normal resting 
ECG found that 12.4% patients had asymptomatic coronary artery disease 
on exercise treadmill testing. The abnormalities of exercise test were 
associated with longer duration of diabetes ( p< 0.005 ). 
There is paucity of data correlating the prevalence of silent 
myocardial ischemia with duration of diabetes. So Further studies are 
needed to state whether or not there is relationship between duration of 
diabetes and asymptomatic coronary artery disease. 
Asymptomatic CAD and associated peripheral neuropathy 
Peripheral neuropathy is a common microangiopathic complication 
of diabetes. In the present study, it was found that 55.55% (10/18) with 
peripheral neuropathy asymptomatic coronary artery disease while only 
15.62 (5/32) without peripheral neuropathy had asymptomatic coronary 
artery disease. Thus, in our study diabetics with peripheral neuropathy 
had a greater incidence of asymptomatic coronary artery disease than 
those without it.(55.55% Vs 15.62%). 
Our findings are in agreement with one study
17
 who found that 
silent myocardial ischemia was associated with presence of diabetic 
polyneuropathy. One study
45
 found that 61.5% subjects with peripheral 
neuropathy had silent myocardial ischemia while only 11.1% without 
peripheral neuropathy had silent myocardial ischemia. However, our 
study is not in agreement with the one study
16
, who found that there was 
no difference in prevalence of silent myocardial ischemia in patients with 
or without peripheral neuropathy. The reason for this disparity could have 
been due to the fact that peripheral neuropathy in their study was 
diagnosed by nerve conduction studies, which might have detected 
neuropathy at an early stages, probably at that time they did not find 
evidence of asymptomatic CAD disease along with peripheral 
neuropathy. 
Asymptomatic CAD and associated autonomic neuropathy 
In our study, 75% of subjects (9/12) with autonomic neuropathy 
had asymptomatic CAD while only 21.95% of subjects (6/38) without 
autonomic neuropathy had asymptomatic coronary artery disease. Thus, it 
was seen that, diabetics with autonomic neuropathy had higher incidence 
of associated asymptomatic CAD than those without it. (75% Vs 
21.95%). This is in agreement with majority of studies. One group
19 
found that in a diabetic population of known or suspected coronary artery 
disease had silent myocardial ischemia much more common with 
autonomic neuropathy. (92% Vs 39%). Another group
22
, reported that 
17% of diabetic population had silent myocardial ischemia on holtor or 
exercise electrocardiogram which was more common in those with 
autonomic neuropathy (38% Vs 5%). In one more study
24
 the incidence 
of asymptomatic CAD was found to be 37.5% who had evidence of 
autonomic neuropathy (76.9%). One study in India
25
 found 38.3% to have 
silent myocardial ischemia with a greater prevalence in those with 
autonomic neuropathy (59%) than those without it( 20%). Another 
study
46
 from India found that incidence of silent myocardial ischaemia 
was significantly higher in patients with autonomic neuropathy. 12/13 
(40%) compared to those without 3/30 (10%) .     
Dyslipidemia and coronary artery disease 
Lipid profile abnormalities are very common in type 2 diabetes and 
it has great influence on CAD. In the present study, we found average 
total cholesterol in TMT positive and negative cases was 201.33 mg% 
and 185.57 mg% respectively. Average triglyceride in TMT positive and 
negative cases was 156.60 mg% and 125.46 mg% respectively. 
Statistically significant value of p =0.0094 was found in triglyceride 
levels between both the groups. This was in similar with previous study
47 
which found that dyslipidemia was very common in type 2 diabetics and 
the most common abnormality seen was increased serum triglyceride 
levels (73.3%) The next common abnormality was decreased serum HDL 
and LDL levels. Both seen in 66.7%. Coronary artery disease had a 
stronger correlation with high levels of triglycerides. The other study 
from India
48
, found that CAD had strong correlation with high levels of 
VLDL (0.76) triglycerides (0.82), LDL (0.23) and low HDL (- 0.81). 
One
49
 of the studies found that frequency of hyperlipidemia in CAD was 
high. They found that CAD had high cholesterol levels (p=0.04) than 
those without it. The other study
29
 found that cholesterol and triglyceride 
levels were elevated in 28 treadmill positive cases compared to 15 
treadmill negative cases. (p<0.01). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Conclusions           
 
CONCLUSION 
1.  The prevalence of asymptomatic coronary artery disease in type 2 
diabetes mellitus without past history of ischemic heart disease or 
hypertension is 30%, 
2.  Longer the duration of diabetes, greater the risk of asymptomatic 
coronary artery disease. 
3.  Dyslipidemia was found to be more in diabetics who had greater 
prevalence of asymptomatic coronary artery disease on TMT. 
4.  Diabetics with clinical peripheral neuropathy and autonomic 
neuropathy had higher incidence of asymptomatic coronary artery 
disease. 
5.  Early screening of patients with type 2 diabetes mellitus for the 
evidence of asymptomatic coronary artery disease may prevent 
catastrophic cardiac events. 
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Annexures  
PROFORMA 
“PREVALENCE OF ASYMPTOMATIC CORONARY ARTERY 
DISEASE   IN TYPE-2 DIABETES MELLITUS PATIENTS” 
 
I) Patient identification data 
Name :                           IP/OPD No  :  
Age :    Sex  :    
Occupation :    Address :  
 
II)   Clinical profile 
History          :                                          Duration of DM :  
  
III) Symptoms related to diabetes mellitus  
Polyuria / Nocturia  
Polyphagia  
Polydypsia  
Weight loss  
Delayed wound healing  
 IV) Symptoms suggestive of microvascular complications Nephropathy  
Puffiness of face / swelling of feet  
Oliguria / anuria  
Recurrent UTI  
Retinopathy  
Visual loss – Total / Partial  
Blurring of vision  
Peripheral neuropathy  
Numbness  
Parasthesias  
Pain  
Proximal muscle weakness  
Autonomic neuropathy  
Presyncope / syncope  
Palpitations  
Gustatory sweating  
Anhydrosis  
Nocturnal diarrhea / faecal incontinence  
Urinary incontinence  
Impotence  
Treatment history  
Diet alone 
Oral hypoglyacemic agents  
Insulin  
OHA + Insulin  
Family history  
DM/HTN/IHD  
Personal history  
Diet  
Habits  
Menstrual history  
Oral contraceptives  
General physical examination  
Weight in kgs  
Height in mtr.                                             BMI  
Hip Waist circumference 
Face: puffiness  
Eyes                                                           Fundus 
Pallor  
Pigmentation  
Odema  
Deep vein thrombosis  
Vital signs  
Pulse    
Blood pressure - Supine  and Standing  
Systemic examination  
Respiratory system  
Cardiovascular system  
Per abdomen  
Central nervous system  
Investigative profile  
A)  Hematological  
Hemoglobin  
TLC/DLC  
B) Biochemical   
Fasting blood sugar  
Post prandial blood sugar  
Fasting lipid profile  
Cholestrol  
Triglyceride  
HDL  
LDL  
Urea  
S. Creatinine  
HbA1C 
 
C) Urine examination   
Routine and microscopic examination  
Microalbuminuria 
D) X-ray chest (PA) view:  
E) Electrocardiogram  
F) Treadmill test 
 
 
 
 
 
 
 
 
 
 
 
S No Age Sex IP No.
Duration 
of DM
symptoms 
of DM
P neuropathy 
symptoms
Autonomic 
N symptoms
Treatment 
history
Family 
history
BMI Pulse SBP DBP CVS P Neuropathy A Neuropathy HbA1C FBS PPBS T Cholesterol TGL HDL LDL Urea Creatinine
Urine 
albumin
CXR TMT
1 54 M 61223 3 ₋ - - O + 21.8 70 132 80 N ₊  - 9.5 233 358 200 150 32 90 26 1.1  -  N ₊
2 51 M 1556 2 ₋ - - O + 26.6 80 130 90 N ₋  - 8.4 168 215 150 140 38 84 24 0.8  -  N ₋
3 63 F 43371 19 ₊ ₊ ₊ I - 38 86 140 90 N ₋ ₊ 9.4 291 336 240 200 30 134 40 0.8  -  N ₊
4 46 M 3987 9 ₋ ₊ - O + 20.2 84 136 90 N ₊ ₊ 7.7 145 170 173 120 32 117 34 0.8  -  N ₋
5 56 M 4902 2 ₋ - - O + 24.4 78 140 90 N ₋  - 8 180 260 150 120 40 86 32 1.4  -  N ₋
6 49 M 27746 3 ₋ - - O + 27.3 76 120 90 N ₊  - 7.7 160 190 173 100 40 113 30 0.7  -  N ₊
7 58 F 8453 15 ₋ ₊ - I + 26.9 80 130 80 N ₊  - 8.6 154 206 234 180 40 158 36 0.9  -  N -
8 33 F 23749 2 ₋ - - OI + 23.1 70 140 90 N  -  - 9.4 168 204 225 190 40 147 22 0.8  -  N -
9 62 M 8442 7 ₋ - - O - 20.4 78 136 80 N  -  - 7.2 125 170 170 130 40 104 36 0.9  -  N -
10 58 M 28394 4 ₋ - - O + 19.4 78 140 90 N  - ₊ 11.6 136 204 160 90 32 110 22 0.5  -  N ₊
11 34 M 7453 12 ₋ ₊ - I + 20.5 74 130 70 N ₊ ₊ 10.5 158 324 173 140 40 105 30 0.7  -  N -
12 52 M 29839 4 ₋ - - O + 24.6 80 120 80 N ₋ ₋ 8.5 146 216 180 100 34 126 20 0.9  -  N -
13 44 M 3244 14 ₋ ₊ ₊ I - 21.2 86 124 70 N ₊ ₊ 7.7 175 178 174 80 32 126 30 0.4  -  N -
14 65 M 678 17 ₊ ₊ - I - 26.2 84 126 80 N ₊ ₊ 7.4 233 168 200 100 32 100 26 0.9  -  N -
15 58 M 14789 1 ₊ - - D + 26.9 90 140 80 N ₊  - 7.6 136 180 133 128 32 75 28 0.8  -  N ₊
16 56 M 9744 5 ₋ - - OI + 27.3 84 146 90 N  -  - 7.8 148 186 212 188 30 139 22 0.6  -  N -
17 48 M 4778 3 ₋ - - O - 22.5 86 130 80 N  -  - 7.4 154 176 150 80 34 100 24 0.7  -  N -
18 54 F 23747 4 ₋ - - O + 20.4 96 140 80 N  -  - 7.6 128 190 152 82 34 102 30 0.5  -  N ₊
19 38 M 8887 8 ₋ - - OI - 19.4 76 130 80 N  -  - 7.4 148 204 207 154 36 140 34 0.5  -  N -
20 67 M 9432 3 ₊ - ₊ O + 19.6 78 130 80 N ₊  - 7.2 152 216 164 140 38 98 32 0.6  -  N -
21 68 M 7920 9 ₊ ₊ ₊ O + 27.3 72 124 80 N ₊ ₊ 11.2 204 358 173 100 40 113 38 0.6  -  N ₊
22 56 F 67889 2 ₋ ₋ - O - 28.2 68 126 70 N ₋  - 8.9 190 186 234 210 30 165 32 0.9  -  N ₊
23 46 M 2847 13 ₋ ₊ - I - 26.8 70 128 80 N ₊  - 7.9 176 176 225 160 36 110 28 0.9  -  N -
24 53 M 71234 5 ₋ - - OI + 32.1 68 114 70 N  -  - 8.8 186 190 240 250 34 152 26 0.8  -  N -
25 55 M 63821 3 ₋ - - O - 23.4 72 120 80 N  -  - 8.8 175 170 174 174 32 90 30 0.4  -  N -
S No Age Sex IP No
Duration 
of DM
symptoms 
of DM
P neuropathy 
symptoms
Autonomic 
N symptoms
Treatment 
history
Family 
history
BMI Pulse SBP DBP CVS P Neuropathy A Neuropathy HbA1C FBS PPBS T Cholesterol TGL HDL LDL Urea Creatinine
Urine 
albumin
CXR TMT
27 57 M 7364 15 ₊ ₊ - I + 26.3 84 130 70 N ₊ ₊ 7.9 136 190 133 140 34 134 28 0.8  -  N ₊
28 44 M 7942 10 - ₊ - O + 25.5 86 136 90 N ₊  - 8.8 148 206 212 136 34 117 22 0.8  -  N -
30 51 M 66879 2 - - - O + 23.4 80 128 80 N  -  - 8.6 128 210 200 164 40 113 30 0.4  -  N -
31 55 M 56726 2 - - - O + 34.2 86 120 70 N  -  - 9.4 186 178 286 204 30 146 34 0.9  -  N -
32 49 M 1388 12 - ₊ - O + 20.7 84 136 80 N  -  - 7.2 136 180 170 120 40 96 32 0.8  -  N ₊
33 42 M 3744 8 - - - O - 23.4 72 128 70 N  -  - 11.6 240 324 164 110 32 112 38 0.6  -  N ₋
34 48 F 8893 4 ₊ - - OI + 23.8 88 126 70 N ₊ ₊ 7.9 136 158 150 96 40 56 22 0.7  -  N ₊
35 35 M 29848 5 ₊ - ₊ OI + 32 68 130 80 N ₊  - 8.8 236 360 240 199 34 156 24 0.5  -  N ₊
36 56 M 14589 4 ₋ - ₋ O - 22 68 118 70 N ₋  - 7.4 158 196 144 100 32 86 30 0.5  -  N ₋
37 57 M 546 16 ₊ ₊ ₊ I - 24.6 72 130 80 N ₊ ₊ 7.6 146 204 178 112 40 104 20 0.6  -  N ₊
38 45 F 46821 7 - - - O + 21.4 76 120 80 N  -  - 7.4 175 210 150 126 40 90 30 0.9  -  N -
39 64 M 9848 9 - - - I + 23 84 130 80 N  -  - 7.6 138 178 133 158 40 88 26 0.8  -  N -
40 58 M 26366 3 - - - OI + 23.3 86 140 90 N  -  - 8.4 291 180 170 134 40 114 28 0.6  -  N ₊
41 44 M 36767 2 - - - O - 20.5 74 136 80 N  -  - 8.2 185 206 165 122 40 94 40 0.7  -  N ₋
42 47 F 8484 9 ₊ ₊ - I + 21.2 78 140 80 N ₊  - 7.8 180 188 158 146 32 108 34 0.6  -  N ₊
43 58 M 7598 7 ₋ - - I + 28.1 76 130 80 N ₋  - 7.2 204 180 210 206 30 142 32 0.7  -  N -
44 54 M 64622 3 ₊ ₊ - O + 27.2 80 120 70 N ₊ ₊ 9.4 235 310 214 214 34 129 30 0.5  -  N -
45 41 M 8764 9 - - - I - 23.7 70 124 70 N  - ₊ 8.6 176 196 188 136 32 98 36 0.5  -  N -
46 46 M 9576 5 - - - OI + 34.2 78 136 80 N  -  - 7.4 142 170 234 218 32 138 30 0.6  -  N -
47 47 M 46587 4 - - - O - 26.3 86 132 80 N  -  - 7.6 146 168 155 100 34 92 26 0.6  -  N - 
48 42 M 5788 6 - - - O + 23.8 74 120 70 N  -  - 7.5 140 184 167 98 40 88 28 0.9  -  N -
49 48 M 23774 5 - - - OI + 23.2 80 132 80 N  -  - 8 168 198 174 112 38 76 40 0.8  -  N - 
50 37 M 36246 2 - - - O + 22 76 136 80 N  -  - 8.2 246 310 246 186 38 64 34 0.8  -  N - 
CONSENT FORM 
Yourself Mr/Mrs/Ms  _________________ are  being asked to be a 
participant in the study titled – “To study the prevalence of 
Asymptomatic Coronary Artery Disease in type 2 Diabetes Mellitus” in 
CMC Hospital Conducted by Dr. Suja P Sukumar, Post Graduate student, 
Department of General Medicine, Coimbatore Medical College. You are 
eligible after looking into inclusion  criteria. You can ask any questions 
you may have before agreeing to participate.  
Purpose of the research  
1.   To study the prevalence of asymptomatic CAD in type 2 diabetes 
mellitus.  
2. To study the relation of asymptomatic CAD with duration of 
diabetes mellitus.  
Procedures involved  
This research is intended to study type 2 diabetes mellitus patients 
without clinical and ECG evidence of ischemic heart disease to perform 
treadmill test using Bruce Protocol for the presence of asymptomatic 
CAD.  
 
 
Decline from participation  
You have the option to decline from participation in the study 
without any discrimination and you will be treated as per the existing 
protocol for your condition. 
Privacy and confidentiality  
Privacy of individual will be respected and any information about 
you or  provided by you during the study will be kept strictly confidential. 
Authorization publish results  
Results of the study may be published for scientific purposes and / 
or  presented to scientific groups; however you will not be identified. 
 
Statement of Consent   
I volunteer and consent to participate in this study. I have read the 
consent or it has been read to me. The study has been fully explained to 
me and I may ask questions at any time.  
 
________________________________            _______________  
Signature of Left Hand thumb Impression           Date  
(Volunteer Subject)       
 
 
______________________________     ________________  
Signature (Witness)           Date  
ABBREVIATIONS 
AGE - Advanced glycated end products 
BMI - Body mass index 
CABG - Coronary Artery Bypass Grafting 
CAD - Coronary Artery Disease 
ECG - Electro cardiography 
ESRD - End stage renal disease 
FPG - Fasting plasma glucose 
GDM - Gestational Diabetes Mellitus 
HbA1C/A1C - Glycosylated hemoglobin 
HDL - High density lipoprotein 
TGL - Triglyceride 
LDL - Low density lipoprotein 
LP(a) - Lipoprotein a 
IDL - Intermediate density lipoprotein 
IFG - Impaired Fasting glucose 
IGT - Impaired Glucose tolerance 
LBBB - Left Bundle branch block 
LVH - Left Ventricle hypertrophy 
MI - Myocardial infarction 
NAD - Nicotinamide Adenosine Diphosphate 
NADH - Nicotinamide adenosine Diphosphate Hydrogenase 
NPDR - Non Proliferative Diabetic Retinopathy 
OGTT - Oral glucose tolerance test 
PDR - Proliferative Diabetic Retinopathy 
THR - Target Heart Rate  
SBP - Systolic Blood Pressure 
DBP - Diastolic Blood Pressure 
OHA - Oral Hypoglycemic Agent 
TMT - Treadmill test 
VLDL - Very low density lipoprotein 
 
  
 
